Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

PROSTACOX : Metastatic Prostate Chemotherapy

This study has been completed.
Sponsor:
Information provided by:
University Hospital, Rouen
ClinicalTrials.gov Identifier:
NCT00213694
First received: September 13, 2005
Last updated: March 4, 2013
Last verified: March 2013
  Purpose

Clinical response to chemotherapy. Biological parameter (PSA) and RECIST evaluation. Association of Docetaxel (J 15) and Celecoxib.


Condition Intervention Phase
Metastatic Prostate Cancer
Drug: docetaxel and celecoxib
Phase 2

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Efficacy of Docetaxel (J 15) and Celecoxib in Metastatic Prostate Cancer

Resource links provided by NLM:


Further study details as provided by University Hospital, Rouen:

Estimated Enrollment: 52
Study Start Date: November 2003
Estimated Study Completion Date: June 2006
Detailed Description:

Association Docetaxel (J 15) and celecoxib Patient survival Biological parameter : PSA Clinical status RECIST evaluation

  Eligibility

Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • metastatic prostate cancer
  • ASCO progression criteria

Exclusion Criteria:

  • other prostate chemotherapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00213694

Locations
France
Charles Nicolle, University Hospital
Rouen, France, 76031
Sponsors and Collaborators
University Hospital, Rouen
Investigators
Principal Investigator: Christian PFISTER, MD, PhD University Hospital, Rouen
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00213694     History of Changes
Other Study ID Numbers: 2003/052/HP
Study First Received: September 13, 2005
Last Updated: March 4, 2013
Health Authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Diseases, Male
Genital Neoplasms, Male
Neoplasms
Neoplasms by Site
Prostatic Diseases
Urogenital Neoplasms
Celecoxib
Docetaxel
Analgesics
Analgesics, Non-Narcotic
Anti-Inflammatory Agents
Anti-Inflammatory Agents, Non-Steroidal
Antimitotic Agents
Antineoplastic Agents
Antirheumatic Agents
Central Nervous System Agents
Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses
Tubulin Modulators

ClinicalTrials.gov processed this record on November 25, 2014